Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.

PloS one - 1 Jan 2009

Rosell Rafael, Perez-Roca Laia, Sanchez Jose Javier, Cobo Manuel, Moran Teresa, Chaib Imane, Provencio Mariano, Domine Manuel, Sala Maria Angeles, Jimenez Ulpiano, Diz Pilar, Barneto Isidoro, Macias Jose Antonio, de Las Peñas Ramon, Catot Silvia, Isla Dolores, Sanchez Jose Miguel, Ibeas Rafael, Lopez-Vivanco Guillermo, Oramas Juana, Mendez Pedro, Reguart Noemi, Blanco Remei, Taron Miquel

Abstract excerpt

BACKGROUND: Median survival is 10 months and 2-year survival is 20% in metastatic non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy. A small fraction of non-squamous cell lung cancers harbor EGFR mutations, with improved outcome to gefitinib and erlotinib. Experimental evidence suggests that BRCA1 overexpression enhances sensitivity to docetaxel and resistance to cisplatin. RAP80 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Docetaxel

Share to Drug Dosage Calculations

Share to Gemcitabine

Share to Histone Chaperones

Share to RNA, Neoplasm

Share to Taxoids

Source

Open in PubMed Open full text

Identifiers

PMID: 19415121
DOI: 10.1371/journal.pone.0005133
PMCID: PMC2673583

Genes

BRCA1
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.PMID 19415121Read ↗

Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.Semantic proximity Read ↗

Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.Semantic proximity Read ↗

Biomarkers in lung oncology.Semantic proximity Read ↗

Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.Semantic proximity Read ↗

Individualized treatment of NSCLC: from research to clinical practice.Semantic proximity Read ↗

From the bench to the bed: individualizing treatment in non-small-cell lung cancer.Semantic proximity Read ↗

Personalized medicine for non-small-cell lung cancer.Semantic proximity Read ↗

The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer.Semantic proximity Read ↗

Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.Semantic proximity Read ↗

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Semantic proximity Read ↗

Predicting Personalised Therapeutic Combinations in Non-Small Cell Lung Cancer Using In Silico ModellingSemantic proximity Read ↗

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.